series-b
Stage
1
Investors
About
Seneca Therapeutics develops oncolytic immunotherapeutic candidates, including the Seneca Valley Virus (SVV-001), designed to selectively target and treat solid tumors by replicating in tumor cells expressing the TEM8 receptor.
Explore Seneca Therapeutics, Inc's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.